Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Discover the challenges and opportunities for Keros Therapeutics, Inc., including FDA designations, partnerships, and ...

Morning. Today, we see fallout from the FDA’s rejection of Replimune’s melanoma drug affecting another biotech, learn how Sarepta’s decision-making has affected a patient population that hasn’t always ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Some experts worry that patient groups’ growing influence is leading to the approval of drugs that may not work and could ...

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected ... that defendants made false statements and/or concealed that: (i) ELEVIDYS, a ...

Learn more about whether ADMA Biologics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...